Literature DB >> 7817480

Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer.

J C Angulo1, J I Lopez, D J Grignon, M Sanchez-Chapado.   

Abstract

OBJECTIVES: Contrary to previous belief, the existence of a muscularis mucosa in the human urinary bladder has now been well described. Although the degree of development of this structure seems variable, it can frequently be used to differentiate two levels within the subepithelial connective tissue: the lamina propria and the submucosa. The present study evaluates whether this morphologic feature is potentially useful for the identification of two populations with Stage T1 bladder cancer: those with tumor invasion confined to the lamina propria (pT1A) and those with tumors infiltrating into the submucosa (pT1B).
METHODS: A series of 170 Stage T1 papillary bladder tumors was analyzed pathologically to identify the level of subepithelial connective tissue invasion. Both the reproducibility of such a differentiation and its prognostic implication were evaluated using Kaplan-Meier survival estimates and the Cox regression model.
RESULTS: In specimens from transurethral resection, categorization into T1A or T1B could be performed in 98 of 170 cases (58% of specimens). Such differentiation proved to be of prognostic value with significantly different 5-year survivals between the two subcategories (pT1A [n = 50] vs pT1B [n = 49]) (log-rank, P < 0.02). Cox's regression analysis of pT1 subcategory and grade was performed in the 99 cases in which the differentiation between pT1A/pT1B could be made. This demonstrated that the depth of subepithelial connective tissue invasion was an independent prognostic factor (P < 0.05).
CONCLUSIONS: The depth of tumor infiltration can be assessed in a considerable proportion of Stage T1 bladder neoplasms. The present study validates the prognostic significance of such a distinction both by Mantel-Haenszel life table method and Cox's regression analysis.

Entities:  

Mesh:

Year:  1995        PMID: 7817480     DOI: 10.1016/s0090-4295(95)96490-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Bladder cancer: narrowing the gap between evidence and practice.

Authors:  Maha H A Hussain; David P Wood; Dean F Bajorin; Bernard H Bochner; Robert Dreicer; Donald L Lamm; Michael A O'Donnell; Arlene O Siefker-Radtke; Dan Theodorescu; Colin P Dinney
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

2.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

3.  Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance.

Authors:  José I López; Javier C Angulo
Journal:  Int Urol Nephrol       Date:  2009-03-12       Impact factor: 2.370

4.  Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder.

Authors:  Vincenzo DE Marco; Maria Angela Cerruto; Carolina D'Elia; Matteo Brunelli; Oscar Otte; Anila Minja; Claudio Luchini; Giovanni Novella; Stefano Cavalleri; Guido Martignoni; Walter Artibani
Journal:  Mol Clin Oncol       Date:  2014-05-08

5.  The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.

Authors:  Fikret Erdemir; Faruk Ozcan; Isin Kilicaslan; Bekir S Parlaktas; Nihat Uluocak; Ozgur Gokce
Journal:  Int Urol Nephrol       Date:  2007-03-06       Impact factor: 2.370

Review 6.  Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?

Authors:  Boris Gershman; Stephen A Boorjian; Richard E Hautmann
Journal:  Bladder Cancer       Date:  2015-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.